Abstract: A composition for treating wood-based material including at least one C1-C7 monocarboxylic acid salt or C1-C7 monocarboxylic acid or a mixture thereof as active agent against deteriation of wood. The composition also includes alkyd emulsion of high unsaturated fatty acid content and/or aluminum ion containing compound in the form of polyaluminum formate in a same aqueous liquid carrier as the C1-C7 monocarboxylic acid salt or C1-C7 monocarboxylic acid or a mixture thereof.
Type:
Application
Filed:
November 25, 2009
Publication date:
June 28, 2012
Inventors:
Juha Estakari, Toivo Mertaniemi, Jari Jussila, Juha Kuusisto, Reijo Saunamäki, Norberto Mancuso
Abstract: Provided herein are methods of treating gastrointestinal motility disorders by targeting the dopamine 3 receptor (D3R). A D3R agonist is administered to a subject to decrease gastrointestinal motility to treat the disorder. A D3R antagonist is administered to a subject to decrease gastrointestinal motility to treat the disorder.
Type:
Application
Filed:
March 6, 2012
Publication date:
June 28, 2012
Applicant:
The Board of Regents of the University of Texas System
Inventors:
Pankaj Jay Pasricha, Maria-Adelaide Micci
Abstract: In one embodiment of the present invention, a pharmaceutically-acceptable single-dosage formulation consists essentially of about 300 mg of vitamin C; about 1200 IUs of vitamin D3; about 125 IUs of vitamin E; about 25 mg of vitamin B1; about 3.4 mg of vitamin B2; about 35 mg of niacin; about 35 mg of vitamin B6; about 1.25 mg of folate; about 70 mcg of vitamin B12; about 5 mg of pantothenic acid; about 300 mcg of biotin; about 50 mg of calcium; about 35 mg of magnesium; about 35 mg of zinc; about 1 mg of copper; about 125 mcg of selenium; about 150 mcg of chromium; about 25 mg of alpha lipoic acid; about 35 mg of co-enzyme Q-10; about 2 mg of lutein; about 500 mcg of lycopene; about 5 mg of pepper extract; and at least one or more excipients.
Type:
Grant
Filed:
February 2, 2010
Date of Patent:
June 19, 2012
Assignee:
Vertical Pharmaceuticals, Inc.
Inventors:
Steven A. Squashic, Kevin M. Hudy, David C. Purdy
Abstract: The invention relates to a combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor, said preparation being adapted for (a) the administration of parathyroid hormone during a period of approximately 6 to 24 months; (b) after the administration of parathyroid hormone has been terminated, the administration of a bone resorption inhibitor during a period of approximately 12 to 36 months.
Type:
Application
Filed:
February 24, 2012
Publication date:
June 14, 2012
Applicant:
NPS Pharmaceuticals, Inc.
Inventors:
John Dietrich, Sverker Ljunghall, Sven Sjögren
Abstract: The present invention relates to galvanic particulates, their methods of manufacture and uses in treatments are described. The galvanic particulates may be binary or tertiary galvanic particulates, for example, containing multiple layers or phases of conductive materials.
Type:
Application
Filed:
March 25, 2010
Publication date:
June 14, 2012
Inventors:
Ying Sun, Jue-Chen Liu, Michael Southall, Luiz Arthur Bonaci Tessarotto, Leon B. Kriksunov
Abstract: A nutritional composition for treating severe headaches and comprising a plurality of vitamins and a plurality of minerals that together represent at least a portion of required daily allowance thereof. The plurality of vitamins include at least vitamins A, C, D, E, K, B-1, B-2, B-6, and B-12, niacin, folic acid, biotin, pantothenic acid, and mixtures thereof, while the plurality of minerals include at least selenium, zinc, magnesium, calcium, iron, manganese, copper, chromium, cobalt, phosphorous, iodine, potassium and molybdenum. The composition further includes at least one or both of 125-175 mg of co-enzyme Q-10 and 25-150 mg of purified Butterbur root extract.
Abstract: A nutritional supplement for use in physiologically stressful conditions is disclosed. The nutritional supplement may include one or more of vitamin A, vitamin E, vitamin D3, vitamin C, vitamin B1, riboflavin, niacin, folic acid, vitamin B6, biotin, pantothenic acid, vitamin B12, magnesium, zinc, selenium, chromium, copper, iron, alpha lipoic acid, lutein and lycopene.
Type:
Grant
Filed:
March 7, 2011
Date of Patent:
June 12, 2012
Assignee:
Vertical Pharmaceuticals, Inc.
Inventors:
Steven A. Squashic, Kevin M Hudy, David C. Purdy
Abstract: The present invention relates to compositions that may be swallowable, chewable or dissolvable, comprising various vitamins and minerals, and in a specific embodiment comprising vitamin A, beta carotene, B-complex vitamins, vitamin C, vitamin D3, vitamin E, iron, magnesium and zinc, and methods for using these compositions for nutritional supplementation in subjects undergoing physiologically stressful events, such as, for example and without limitation, pregnancy, lactation or any disease state.
Abstract: Novel etiology underlying certain types of seizures and migraines is presented, whereby changes in endocrine levels result in changes in osteoclast activity levels which in turn result in elevated extracellular Ca2+ levels which in turn result in systemic alterations in nerves muscles, including increased nerve membrane depolarization, enhanced calcium channel mediated neurotransmitter release, and increased muscle contractility via sarcoplasmic reticulum calcium release channel mediated tropomyosin block removal, which in turn result in increased seizure risk in people with low seizure thresholds. Treatment methods are provided that modulate the bone microenvironment to provide an etiology based seizure treatment method that simultaneously reduces nerve sensitivity and muscle contractility. Preferred embodiments include use of SERMs such as raloxifene, testosterone, estrogen, calcimimetics such as cinacalcet, RANKL inhibitors such as denosumab, and bisphosphonate such as risedronate.
Abstract: Disclosed is a sterilizer for foods, which contains calcinated calcium or calcium hydroxide and has a higher sterilizing activity than conventional sterilizers. The sterilizer is made up of an aqueous solution or an aqueous dispersion prepared by blending calcinated calcium or calcium hydroxide, ethanol, and sodium lactate.
Abstract: Phosphatidic acid is administered orally to increase muscle mass and strength in exercising mammals. Phosphatidic acid is administered orally to aging, bedridden or cachectic patients to improve nitrogen balance. The preferred form of phosphatidic acid for administration is phosphatidic acid-enriched lecithin. Creatine is co-administered orally to increase the muscle-building and strength effect. Other suggested additives include nutritional and herbal supplements, micronutrients and hormones.
Type:
Application
Filed:
November 23, 2011
Publication date:
June 7, 2012
Inventors:
Lorenzo De Ferra, Marvin Heuer, Scott Hagerman, Martin Purpura, Ralf Jäger
Abstract: The present invention relates to pharmaceutical compositions comprising dextromethorphan or a physiologically acceptable salt thereof, quercetin, resveratrol, and hesperidin. The invention further relates to nutraceutical or dietary supplement composition comprising a physiologically acceptable salt of magnesium, quercetin, resveratrol, and hesperidin. Further provided are methods for treating respiratory disease in a human subject by substantially eliminating phlegm from the lung through administering to the subject effective amounts of compositions of the invention.
Abstract: A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided.
Abstract: A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided.
Abstract: A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided.
Abstract: The disclosure relates to compositions for treating and/or preventing fire blight in plants or parts thereof, to their methods of production, to concentrates for producing said compositions and to uses and methods based on said compositions.
Abstract: The present invention relates to methods of prognosing the survival of a diseased subject, particularly a subject with chronic kidney disease (CKD), as well as selecting an end-stage renal disease subject for a kidney transplant. The methods involve detecting an elevated amount of macrophage inhibitory cytokine-1 (MIC-1) in a test body sample from the diseased subject. A method of preventing or reducing the risk of death in a CKD subject which involves removing or inactivating MIC-1 present in the blood, plasma or serum of the subject, is also disclosed.
Type:
Application
Filed:
October 29, 2009
Publication date:
May 3, 2012
Applicant:
St Vincent's Hospital Sydney Limited
Inventors:
Samuel Norbert Breit, David Alexander Brown
Abstract: In one aspect, the present invention provides methods of determining susceptibility to bone fracture in a mammalian subject, wherein the methods comprise analyzing nucleic acid molecules obtained from the mammalian subject to determine which of the P, p X, and x alleles of the estrogen receptor ? gene are present, wherein the presence of a haplotype comprising the p and x alleles is indicative of an increased susceptibility to bone fracture. The present invention also provides kits for determining susceptibility to bone fracture in a mammalian subject.
Type:
Application
Filed:
April 21, 2011
Publication date:
May 3, 2012
Inventors:
Andreas Gerardus Uitterlinden, Johannes Petrus Thomas Maria Van Leeuwen, Huibert Adriaan Pieter Pols
Abstract: The present invention relates to a product obtained from gastropod spawn, to be used to prepare dermatological, cosmetic or cosmeceutical compositions designed for skin care; said product has the capacity to activate and mobilise skin stem cells, as well as prevent the loss thereof that takes place as a consequence of chronological and premature ageing. The present invention also relates to the process followed in order to obtain said product.
Inventors:
Marta Dominguez Valdes-Hevia, Aurora Brieva Delgado, Salvador Gonzalez Rodriguez, Eduardo Reyes Martin, Jose Carballeira Morado, Ernesto Quintana Gonzalez, Juan Pablo Pivel Ranieri, Antonio Guerrero Gomez-Pamo, Angeles Juarranz De La Fuente, Jesus Espada Regalado, Francisco Sanz Rodriguez
Abstract: Three types of trisiloxane surfactants having the basic formula: MDM? are described wherein the substituents on the differing M and M? groups, in conjunction with pendant polyalkylene oxide substituents on the D group render the surfactant resistant to hydrolysis under either basic or acidic conditions outside the pH range of 6.0 to 7.5. The compositions are useful in agricultural, household and cosmetic applications.
Type:
Application
Filed:
December 8, 2011
Publication date:
April 26, 2012
Applicant:
Momentive Performance Materials Inc.
Inventors:
George A. Policello, Mark D. Leatherman, Wenqing Peng, Suresh K. Rajaraman, Sophia Xia
Abstract: Lipid compositions comprising nuts, seeds, oils, legumes, fruits, grains, and dairy useful in specified amounts as dietary supplements and diet plans designed around and including the aforementioned for the prophylaxis and treatment of numerous diseases are disclosed. The compositions include omega-6 and omega-3 fatty acids where the ratio of the omega-6 to the omega-3 fatty acids and their amounts are controlled based on one or more factors including age of the subject, sex of the subject, diet of the subject, the body weight of the subject, medical conditions of the subject, and climate of the subject's living area.
Abstract: The present invention includes a method of treating or preventing a CNS white matter injury in a patient in need thereof. The invention also includes a method of stimulating proliferation of a CNS cell in a patient in need thereof.
Abstract: A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided.
Abstract: Methods of using an ETB receptor agonist, such as IRL-1620, for the treatment of stroke or cerebrovascular accidents are disclosed. The ETB receptor agonist is used alone or in combination with a second agent useful in the treatment of stroke or other cerebrovascular accident.
Abstract: A pharmaceutical formulation for treating tinea of feet and hands is disclosed, which is composed of Fructus Gleditsia, Alumen and Borneol. Also disclosed is a cream preparative method of the pharmaceutical formulation, which comprises Fructus Gleditsia is decocted with water, and the decocted liquid is dried under decompression into powder, which is formulated to a cream together with the powders of Alumen and Borneol as well as the respective excipients.
Type:
Grant
Filed:
February 12, 2007
Date of Patent:
April 17, 2012
Assignee:
Shen Zhen Bei Ke Lian Pharmaceutical Sci-Tech Co., Ltd.
Abstract: A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolites but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.
Type:
Grant
Filed:
July 7, 2010
Date of Patent:
April 17, 2012
Assignees:
Baxter International Inc., Baxter Healthcare S.A.
Abstract: The invention relates to a composition based on mineral concentrates and a method of preparing this composition. The composition comprises a powder or a mixture of powders containing at least one silicon derivative and at least one trace element other than silicon, as a mixture with a carrier and physiologically acceptable excipients. Application in cosmetology and dermatology for protecting the skin.
Type:
Application
Filed:
October 14, 2011
Publication date:
April 12, 2012
Applicant:
BULGARI PARFUMS
Inventors:
Jean-Claude ALLART, Jean-Marie Lefevre, Jacques Peyrot, Jean-Paul Marty
Abstract: The present invention provides a functionalized composition and resulting functionalized body or prosthesis for in vitro and in vivo use comprising at least one calcium phosphate containing phase that is functionalized with a linker group comprising at least one of an organic acid molecule, a phosphonic acid, an amine, N,N-dicyclohexylcarbodiimide, and 3-maleimidopropionic acid N-hydroxysuccinimide ester, and combinations thereof, and one or more of a chemical and/or a biologically active moieties, wherein the linker group provides for a reactive location for the attachment of the chemical or biologically active moiety, or both, to the calcium phosphate containing phase, and optionally including an unmodified and/or modified calcium aluminate containing phase. The functionalized compositions have a pliable physical property when mixed with water and adhere to natural bone and subsequently harden at ambient temperatures.
Type:
Application
Filed:
July 28, 2011
Publication date:
April 12, 2012
Inventors:
Kenneth A. McGowan, Ellen S. Gawalt, Rachelle Palchesko
Abstract: Compositions, methods and kits to be used as a lubricant and for treatment of a cavity pathology including joint pathology are provided. The composition comprises therapeutically effective amounts of at least one bioactive agent, such as magnesium compound, at least one lubricating agent, such as hyaluronic acid, and at least one cell membrane repairing agent, such as polyethylene glycol. The components of these compositions may be administered by a direct application, an application through a cannula, an intra-articular injection, as a flush fluid during an arthroscopy of the affected area, as a post-arthroscopy injection, or as part of a lavage of the area affected by the intra-articular pathology. In addition, the composition of the present invention may be administered to the patient from a pump or a depot.
Type:
Grant
Filed:
August 3, 2007
Date of Patent:
April 10, 2012
Assignee:
Warsaw Orthopedic, Inc.
Inventors:
Susan J. Drapeau, Josée Roy, Daniel Andrew Shimko
Abstract: The present invention is directed to a stabilized cross-linked hydrogel matrix comprising a first high molecular weight component and a second high molecular weight component that are covalently linked, and at least one stabilizing or enhancing agent, wherein the first high molecular weight component and the second high molecular weight component are each selected from the group consisting of polyglycans and polypeptides. This stabilized hydrogel matrix may be prepared as bioactive gels, pastes, slurries, cell attachment scaffolds for implantable medical devices, and casting or binding materials suitable for the construction of medical devices. The intrinsic bioactivity of the hydrogel matrix makes it useful as a gel or paste in multiple applications, including as a cell attachment scaffold that promotes wound healing around an implanted device, as gels and pastes for induction of localized vasculogenesis, wound healing, tissue repair, and regeneration, as a wound adhesive, and for tissue bulking.
Type:
Application
Filed:
October 4, 2011
Publication date:
March 29, 2012
Inventors:
Francis V. Lamberti, Richard Chris Klann, Ronald Stewart Hill
Abstract: A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided.
Abstract: The present invention provides nutraceutical compositions with enhanced oral bioavailability. The compositions of the present invention include one or more alkylsaccharides admixed with one or more nutraceutical.
Abstract: A method of manufacturing digestible powder that generates a hydride ion (H?) when dissolved in water is provided. A vacuum oven system that can reach 600° C. and 10?5 torr is used within this method. The method according to this current application comprises of ten to eleven steps of vacuuming, heating and hydrogen treatment of coral reef powder. By adding mixtures of magnesium, phosphorus and potassium, the maximum treating temperature and vacuum pressure is lowered. The coral reef powders treated via the ten steps emit hydrogen when dissolved in the water like powders that are treated with a mixture of natural form of magnesium, phosphorus and potassium complex. Those natural form of the magnesium, phosphorous and potassium includes (NH4)MgPO4.6H2O (struvite), MgSO4.KCl.H2O (Kainite), K2SO4.MgSO4.6H2O (Schönite), K2SO4.MgSO4.4H2O (Leonite), and K2SO4.2MgSO4 (Langbeinite).
Abstract: The invention relates to pharmaceutical compositions and treatment regimes useful in treating one or more of the following conditions: inflammation, kidney disease, eye disease, end-organ injury, systemic endotoxemia, and/or vitamin D resistance. The compositions and treatment regimes are also useful in reducing elevated CRP levels and/or elevated pro-inflammatory cytokines.
Abstract: The invention relates to methods for treating bacterial infection of the respiratory tract, including pneumonias, such as ventilator-associated pneumonia, and to methods for treating ventilator-associated tracheobronchitis, comprising administering an effective amount of a salt formulation as an aerosol to the respiratory tract of an individual in need thereof. The formulations can also be used to reduce transmission of pathogen which can infect the respiratory tract, cause pneumonia or cause ventilator-associated tracheobronchitis.
Type:
Application
Filed:
March 26, 2010
Publication date:
March 8, 2012
Applicant:
PULMATRIX, INC.
Inventors:
Robert W. Clarke, Richard Batycky, Wesley H. Dehaan, David L. Hava, Michael M. Lipp, John Hanrahan
Abstract: The present invention relates to isolated haemoglobin from worms belonging to the Nereididae family and its use in cell culture medium, in preservation solutions and as artificial oxygen carrier for transfusion.
Type:
Application
Filed:
May 7, 2010
Publication date:
March 1, 2012
Applicant:
HEMARINA
Inventors:
Morgane Rousselot, Delphine Dutheil, Franck Zal
Abstract: A nutritional supplement composition having therapeutically effective amounts of milk minerals including calcium, a protein source including kappa-casein fragment 106-169, and enzyme-inhibiting peptides is provided for the treatment of body weight conditions. The nutritional supplement composition is administered in amounts effective for limiting weight gain and/or enhancing weight loss, as well as promoting overall good health, in the treatment of body weight conditions, including overweight and obesity.
Type:
Application
Filed:
November 7, 2011
Publication date:
March 1, 2012
Applicant:
University of Tennessee Research Foundation
Inventors:
Michael B. Zemel, Loren S. Ward, Eric D. Bastian, Starla J. Paulsen
Abstract: The composition of the present invention is geared towards treating hyperhidrosis or any condition involving and/or promoting excessive sweating, typically involving the whole body, include hyperthyroidism or similar endocrine disorders; endocrine treatment for prostatic cancer or other types of malignant disorder; severe psychiatric disorders; obesity and menopause. The foamable composition of the present invention is suitable for treating palmar hyperhidrosis; axillary hyperhidrosis; plantar hyperhidrosis; hyperhidrosis of the trunk and/or the thighs; and facial hyperhidrosis; and any combination of them consisting of a therapeutic foamable composition including: an active agent, suitable for the treatment or prevention of hyperhidrosis.
Abstract: The invention includes a microbe-mitigating architectural barrier that includes a barrier forming material, and at least one biocide. The barrier forming material may be a bitumen product, an elastomeric polymer and combinations thereof. The microbe-mitigating architectural barrier may be formed by applying an emulsion composition directly to an architectural surface, or it may be preformed and adhered or otherwise secured to the architectural surface in the form of a sheet or film. The invention also includes architectural assemblies and/or building envelopes that include the microbe-mitigating barrier. Related methods are encompassed within the scope of the invention.
Type:
Application
Filed:
February 16, 2011
Publication date:
February 16, 2012
Inventors:
John Dracopoulos, Lionel Borenstein, Shawn Melancon
Abstract: Disclosed are: a skin whitening agent comprising, as an active ingredient, a complex of carbonic acid and/or bicarbonic acid, a metal and an LF, a decomposition product of the complex, or a complex of carbonic acid and/or bicarbonic acid, a metal and a decomposition product of an LF; and a food, beverage, feed or cosmetic comprising the skin whitening agent. The skin whitening agent can be ingested safely on a daily basis, and exhibits an excellent skin whitening effect.
Abstract: A molluscicidal composition, comprising: a molluscicide; a molluscicidal activity promoting additive comprising a calcium-containing salt of ethylene disuccinic acid or calcium ions and ethylenediamine disuccinic moieties, having at least 1 mole of calcium per mole of ethylenediamine disuccinic acid; and a carrier material edible to molluscs.
Type:
Application
Filed:
January 26, 2010
Publication date:
February 2, 2012
Inventors:
Nicholas John Dixon, Derek Bassett, Reinhard Arndt, Andreas Prokop, Diana Parker, Tianye Chen
Abstract: The present invention relates to compositions and methods for calcifying dental tissue, e.g., preventing or treating dental hypersensitivity. An oral composition of arginine bicarbonate and calcium carbonate promotes the formation of dentinal tubule plugs aided by combining calcium and phosphate in the fluid. In a specific example, an arginine bicarbonate/calcium carbonate mixture blocked dentinal tubules in a model system. In addition to treating dentinal sensitivity, the compositions and methods of the invention provide for calcifying exposed tooth pulp, calcifying the base or all of a pit or fissure in a tooth, and treating a carious lesion.
Type:
Application
Filed:
September 30, 2011
Publication date:
February 2, 2012
Applicant:
The Research Foundation of State University of New York
Inventors:
Israel Kleinberg, Ana Marie Acevedo, Robi Chatterjee
Abstract: The present invention relates to a pesticide composition intended for protecting plants, crops or seeds against fungal diseases or insect damages, and the corresponding methods of protection by application of the said composition. More precisely, the subject of the present invention is a pesticide composition based on a tetrazolyloxime derivative and a fungicide or an insecticide active substance or compound.
Abstract: The invention relates to the use, in a cosmetic or dermatological composition, of a particular water having a pH of between 7.8 and 10 and a total dissolved solids (TDS) concentration of between 10 and 250 mg/l. The invention also relates to a cosmetic or dermatological composition containing this water. The invention relates in particular to a treatment method intended for preventing or delaying the appearance of the effects of intrinsic and/or extrinsic ageing of the skin, or for slowing down the effects thereof; for preventing or reducing pigmentary spots on the skin, or the coloration of hyperpigmented areas of skin; for reducing the pigmentation of the periphery of depigmented areas; for improving the uniformity of the skin coloration; or for lightening the complexion of the skin.
Type:
Application
Filed:
July 20, 2011
Publication date:
January 26, 2012
Applicant:
LVMH RECHERCHE
Inventors:
Robin KURFURST, Kristell LAZOU, Eric PERRIER
Abstract: Metal particulates capable of generating low levels of corrosion current beneficial for pharmaceutical, cosmetic and other medical uses are provided.
Type:
Application
Filed:
July 20, 2011
Publication date:
January 26, 2012
Inventors:
Jeannette Chantalat, Jeffrey C. Geesin, James E. Hauschild, Julia Hwang, Wei Kong, Jue-Chen Liu, William R. Parrish, Michael D. Southall, Brooks Story, Ying Sun, Chunlin Yang
Abstract: An enteral nutrient gel that is excellent at maintaining its solid matter (gel) form in the stomach, does not readily disintegrate or dissolve with a change in pH, is stable in its physical properties even during long-term storage, and can be passed through a feeding tube. The enteral nutrient gel contains agar, alginic acid and/or a salt thereof, soybean protein or a hydrolysate thereof, calcium, magnesium, dextrin, and, optionally, an oligosaccharide, a disaccharide and/or a monosaccharide. A solid composition containing 8 to 30 wt % protein, 2 to 25 wt % fats, and 40 to 70 wt % dextrin is used in preparing the enteral nutrient gel.
Abstract: This invention relates to a multi-configured, transmucosal pharmaceutical dosage form and, more particularly, to a pharmaceutical dosage form which has a single monolithic/heterogeneous layer or a plurality of such layers. The dosage form is suitable for the delivery of one or more pharmaceutical compositions via the buccal, sublingual, rectal, vaginal or transmucosal delivery route in a human or animal body. It provides for selected delivery profiles resulting from, but not limited to, a porosity-enabled composite matrix of one or more layers/components of the pharmaceutical composition/s. The invention also provides for a method of manufacturing said transmucosal pharmaceutical dosage form in a plurality of configurations.
Abstract: A pharmaceutical composition containing a magnesium salt and an osmotic hypertonic agent, like a mannitol, is disclosed. Also disclosed are methods of treating individuals who have suffered a neurological insult, such as traumatic brain injury.
Abstract: The present invention relates to a method of treatment and/or prevention of cardiovascular disease, rheumatoid arthritis, skin cancer, premenstrual syndrome, diabetes and transdermal transport enhancement. The method comprises the administration of a therapeutically effective amount of krill and/or marine oil to a patient. The present invention also relates to a composition for the treatment and/or prevention of these diseases.
Type:
Application
Filed:
August 24, 2011
Publication date:
December 15, 2011
Applicant:
Neptune Technologies & Bioressources Inc.